Wang Xiaozhe, Weaver David T
On-Q-ity, Inc. 610 Lincoln St. Waltham, Massachusetts, 02451, USA.
Am J Cancer Res. 2011;1(3):301-327. Epub 2010 Jan 3.
PARP inhibitors are emerging as a valuable new drug class in the treatment of cancer. Recent discoveries make a compelling case for the complexity of DNA repair biomarker evaluation and underscore the need to examine at multiple biomarkers in a relational manner. This review updates the current trends in DNA repair biomarker strategies in use for the PARP inhibitors and describes the impact of many DNA repair biomarkers on PARP inhibitor benefit in the cancer clinic.
聚（ADP-核糖）聚合酶（PARP）抑制剂正成为癌症治疗中有价值的新型药物类别。最近的发现有力地证明了DNA修复生物标志物评估的复杂性，并强调了以关联方式检测多种生物标志物的必要性。本综述更新了目前用于PARP抑制剂的DNA修复生物标志物策略的趋势，并描述了许多DNA修复生物标志物对PARP抑制剂在癌症临床治疗中疗效的影响。
